ABX203 (HeberNasvac) Granted Cuban Marketing Authorization to Treat Chronic Hepatitis B

Paris, France - December 8th 2015 – ABIVAX (Euronext Paris: FR0012333284 – ABVX), an emerging leader in developing and commercializing anti-viral and vaccine therapies for diseases like HIV/AIDS and chronic Hepatitis B (CHB) and the Center for genetic Engineering and Biotechnology (CIGB), a global leader in biotechnology, today announced that CECMED, the Cuban regulatory authorities, granted the CIGB their first marketing authorization application for ABX203, a first-in-class therapeutic vaccine for treatment of CHBunder the trade name HeberNasvac.

Press contacts

Caroline Carmagnol 

abivax@alizerp.com

+ 33 6 64 18 99 59 or
+ 33 1 44 54 36 65

 Standard: +33 1 53 83 08 41